A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT07490301 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma
PDAC

Interventions

DRUG: Telisotuzumab adizutecan
DRUG: Fluorouracil
DRUG: Folinic acid/ Leucovorina
DRUG: Oxaliplatin
DRUG: Irinotecan

Sponsor

AbbVie